Last reviewed · How we verify

NCT03720743

Effect of Biodanza on Desire, Excitation and Sexual Inhibition

Completed NA Last updated 29 October 2018
What this trial tests

NA trial testing Biodanza in Sexual Desire Disorder in 73 participants. Completed in 1 June 2018.

Timeline
15 January 2018
Primary endpoint
1 March 2018
1 June 2018

Quick facts

Lead sponsorUniversidad de Almeria
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment73
Start date15 January 2018
Primary completion1 March 2018
Estimated completion1 June 2018
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Universidad de Almeria

Who can join

Adults 18 to 30, any sex, with Sexual Desire Disorder or Sexual Arousal Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the objective of this study was to examine the effects of a 10 weeks biodanza program on the sexual desire and inhibition/arousal of a sample of healthy young adults. A randomized clinical study was carried out, involving a total of 86 young adults divided into Intervention Group (BG) and Control Group (CG), carrying out biodanza sessions during 10 weeks. The Sexual Desire Inventory (SDI) and the Sexual Inhibition/Sexual Arousal-Short Form Scale (SIS/SES-SF) were completed before and after the intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sexual Desire Disorder

Currently open trials in the same condition.

Other Universidad de Almeria trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03720743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing